Clinical Trials Logo

Benign Thyroid Nodule clinical trials

View clinical trials related to Benign Thyroid Nodule.

Filter by:
  • None
  • Page 1

NCT ID: NCT06225765 Not yet recruiting - Clinical trials for Benign Thyroid Nodule

A Prospective Trial Comparing Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) and Conventional Open Thyroidectomy

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

To determine if transoral endoscopic thyroidectomy vestibular approach (TOETVA) is a safe and effective procedure compared to traditional open thyroidectomy. Surgical outcomes, patients' satisfaction, voice and swallowing outcomes will be assessed.

NCT ID: NCT06014229 Recruiting - Clinical trials for Benign Thyroid Nodule

Cryoablation and RFA of Benign Thyroid Nodules: Pilot Study

Start date: August 25, 2023
Phase: N/A
Study type: Interventional

This study will evaluate the clinical response and safety of ultrasound guided percutaneous cryoablation and a radiofrequency ablation in the treatment of benign thyroid nodules as an alternative to the surgery. Ablation of benign thyroid nodules with cryoablation will be directed to patients with benign thyroid lesions (two benign cytological examinations) measuring between 5 and 65 mL of volume and less than 40% of cystic component; patients must present with serum free thyroxine (T4) and thyroid stimulating hormone (TSH) between the normal range values, with no signs of thyroiditis by serum antibodies over 100% of the standard values; calcitonin levels in the normal range values. The cryoablation or RFA will be directed in a non-randomized fashion. Clinical, laboratorial and imaging monitoring will be performed in 12 months, including contrast-enhanced ultrasound when indicated, by 1, 3, 6 and 12 months.

NCT ID: NCT05798936 Not yet recruiting - Clinical trials for Benign Thyroid Nodule

Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst

Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

This study aims to compare the efficacy and safety of ultrasound-guided percutaneous ethanol injection and percutaneous polidocanol injection for the treatment of benign cystic and predominantly cystic thyroid nodules.

NCT ID: NCT05132478 Completed - Thyroid Cancer Clinical Trials

The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer

Start date: November 17, 2021
Phase: N/A
Study type: Interventional

118 adults with benign thyroid nodules who were seen at a UW Health clinic for a fine needle biopsy and do not need surgery will be enrolled and can expect to be on study for a one-time visit of up to 60 minutes. Each participant will be randomized to watch one of two videos simulating a patient-surgeon discussion about treatment options for low-risk thyroid cancer with or without emotionally supportive statements.

NCT ID: NCT03566537 Completed - Quality of Life Clinical Trials

Alterations in Quality of Life After Thyroidectomy for Benign Thyroid Disease

Start date: June 11, 2018
Phase:
Study type: Observational [Patient Registry]

To detect any changes in Quality of Life in patients with benign thyroid diseases who undergo thyroidectomy compared to patients with benign thyroid diseases and conservative treatment and healthy subjects.

NCT ID: NCT03535974 Completed - Clinical trials for Benign Thyroid Nodule

Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules

ESSAY
Start date: May 15, 2018
Phase: N/A
Study type: Interventional

Clinical trial with a double-blind, placebo-controlled, crossover design; enrolls approximately 30 euthyroid patients with benign thyroid nodules, who will receive for 6 weeks a spirulina-based supplement, and for another 6 weeks placebo. Thyroid ecography will be performed three times for each patient, and blood tests including TSH, free T4, free T3 and ceruloplasmin/Copper will also be performed 3 times for each patient. It is expected that a decrease in the thyroid nodules occurs with the supplement administration. Compared with placebo there will be a decrease of at least 20% in the volume or the largest diameter of the nodules during the 6-week administration of the supplement.